ABSTRACT
The new antiepileptic drugs perampanel,retigabine,rufinamide and stiripentol have been recently approved for different epilepsy types.Being them an innovation in the antiepileptics armamentarium,a lot of investigations regarding their pharmacological properties are yet to be performed.Besides,considering their broad anticonvulsant activities,an extension of their therapeutic indications may be worthy of investigation,especially regarding other seizure types as well as other central nervous system disorders.Although different liquid chromatographic (LC) methods coupled with ultraviolet,fluores-cence,mass or tandem-mass spectrometry detection have already been developed for the determination of perampanel,retigabine,rufinamide and stiripentol,new and more cost-effective methods are yet required.Therefore,this review summarizes the main analytical aspects regarding the liquid chro-matographic methods developed for the analysis of perampanel,retigabine (and its main active metabolite),rufinamide and stiripentol in biological samples and pharmaceutical dosage forms.Furthermore,the physicochemical and stability properties of the target compounds will also be addressed.Thus,this review gathers,for the first time,important background information on LC methods that have been developed and applied for the determination of perampanel,retigabine,rufinamide and stiripentol,which should be considered as a starting point if new (bio)analytical techniques are aimed to be imnlemented for these drugs.
ABSTRACT
OBJETIVO: Avaliar a evolução clínica e as complicações agudas e tardias de pacientes portadores de neoplasia de cabeça e pescoço localmente avançada submetidos a cirurgia com radio e quimioterapiaadjuvantes. MATERIAL E MÉTODO: No período de maio de 2004 a junho de 2007 foram analisados 39 pacientes com neoplasia de cabeça e pescoço localmente avançada submetidos a ressecção cirúrgica, radio e quimioterapia adjuvantes. RESULTADOS: A idade mediana foi de 54 anos. Estádio III foi observado em 30,8% e estádio IVA em 61,5% dos pacientes. Setenta e sete por cento dos pacientes realizaram radioterapia com dose de 66 Gy. Em relação às complicações agudas,a mais prevalente foi dermatite grau III em 46,2%, e 48,7% dos pacientes apresentaram fibrosecomo complicação tardia. O seguimento mediano foi de 30 meses, com estimativa de sobrevidalivre de doença locorregional de 70% e sobrevida global de 76% em cinco anos. CONCLUSÃO: Esteestudo mostra que, em pacientes com neoplasia de cabeça e pescoço localmente avançada, a cirurgia seguida de radio e quimioterapia apresentam resultados de controle locorregional e sobrevida livre de doença satisfatórios. Nossos resultados, bem como porcentagens de complicações agudas e tardias, estão compatíveis com a literatura.
OBJECTIVE: To evaluate the clinical outcome of patients with locallyadvanced head and neck cancer treated with postoperative concurrent radio-chemotherapy. MATERIAL AND METHOD: Thirtynine patients with locally advanced head and neck cancer submittedto resection of all visible and palpable disease, followed byradiotherapy (6066 Gy in 30 to 33 fractions over a period of 6 to6.6 weeks) and concurrent cisplatin between May 2004 and June2007 were retrospectively analyzed. RESULTS: A predominance of male with a median age of 54 years was observed; 30.8% of patients were in stage III and 61.5% in stage IVA; 77% of patients received a radiation dose of 66 Gy; dermatitis grade III occurred in 46.2% and fibrosis in 48.7% of patients. The 5-year loco-regional failure and overall survival were 30% and 76%, respectively. CONCLUSION: Data show that surgery followed by concurrent radio-chemotherapypresents reasonable rate of loco-regional control and disease-free survival in high-risk patients. Our index of loco-regionaland distant failure and the rate of acute and late complicationare compatible with other series in the literature.